جست‌وجوی استاد و پژوهشگر

Hyun Kooمشاهده پروفایل

استاد

• Biofilms
• Oral Infectious Diseases
• Nanotechnology
• +۳ مورد دیگر

Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.

Ryan Carneyمشاهده پروفایل

دانشیار

• Paleontology
• Epidemiology
• Functional Morphology
• +۵ مورد دیگر

Dr. Ryan Carney is an Associate Professor of Digital Science at the University of South Florida's Department of Integrative Biology (College of Arts and Sciences). His research bridges paleontology and epidemiology, using cutting-edge technologies like 3D imaging, AI, and VR/AR. He studies dinosaur biomechanics (e.g., Archaeopteryx flight mechanics) and mosquito-borne diseases (e.g., malaria, Zika) through NSF/NIH-funded collaborations with agencies like NASA and the CDC. His work integrates citizen science platforms (iNaturalist, Mosquito Alert) for disease surveillance and develops AI tools for mosquito classification. Education: PhD (Brown), MPH/MBA (Yale), B.A.'s in Biology & Art (UC Berkeley) Lab: SCA 107 (focuses on digital paleontology and disease modeling) Research interests span dinosaur functional morphology, epidemiological modeling using GIS/remote sensing, and translating science through immersive technologies. He received awards like the National Geographic Emerging Explorer and multiple USF teaching/research accolades. Awards: CAS Liberal Arts Teaching Award, Outstanding Research Achievement, etc. Grants include NSF funding for AI-driven mosquito surveillance and NIH support for disease control. His lab's innovations include the Global Mosquito Observations Dashboard (GMOD) and VR reconstructions of prehistoric species.

Sharon Rozovskyمشاهده پروفایل

استاد

• Oxidative Stress
• Protein Quality Control
• ERAD Pathway
• +۵ مورد دیگر

Sharon Rozovsky is a Professor in the Department of Chemistry and Biochemistry at the University of Delaware's College of Arts & Sciences, where she leads research on oxidative stress response mechanisms and protein quality control pathways. Her work bridges biochemistry, chemical biology, and structural biology with direct implications for understanding neurodegenerative diseases and viral pathogenesis. Her academic foundation includes a B.S. from Tel Aviv University (1994) and a Ph.D. from Columbia University (2000), establishing her expertise in protein dynamics and redox biochemistry. These credentials underpin her innovative approaches to studying cellular stress responses. Rozovsky's research program centers on selenoproteins—proteins containing the rare amino acid selenocysteine—and their critical roles in endoplasmic reticulum (ER) stress resolution. She investigates how membrane-bound selenoproteins like Selenoprotein S and K regulate the ER-associated degradation (ERAD) pathway, with recent work revealing their surprising autoproteolytic activity and involvement in SARS-CoV-2 replication. Her lab pioneers chemical tools including expressed protein ligation and advanced 77Se NMR spectroscopy to characterize these systems at molecular resolution. Analysis of her 2021-2025 publications shows dominant themes in selenoprotein structure-function relationships, ER stress mechanisms, and viral interactions, alongside methodological innovations in cryo-EM grid technology and NMR. This body of work demonstrates consistent focus on redox biochemistry with expanding applications in virology and structural biology. No major scientific awards or fellowships were explicitly documented in the available materials, though her research impact is evident through high-impact publications and methodological contributions. She directs the active Rozovsky Research Group, mentoring graduate students and postdoctoral researchers in biochemical and biophysical techniques. Her laboratory operations are supported by competitive funding including an NSF CAREER award (2011) focused on selenoprotein reactivity, reflecting sustained recognition of her innovative research program.

Elemir Simkoمشاهده پروفایل

استاد

• Honey bee health
• Agricultural sustainability
• Comparative pathology
• +۳ مورد دیگر

Dr. Elemir Simko is a Professor in the Department of Veterinary Pathology at the University of Saskatchewan, affiliated with Prairie Diagnostic Services. He holds a DVM from the University of Belgrade (Yugoslavia) and a DVSc from the University of Guelph, and is a Diplomate of the American College of Veterinary Pathologists. Since 1998, he has coordinated core anatomic pathology courses at both undergraduate and graduate levels. His research focuses on honey bee health, agricultural sustainability, comparative pathology, and innate immunity. Recent work includes studies on honey bee pathogen dynamics, pesticide impacts, and equine septic arthritis diagnostics using biomarkers. He collaborates extensively with researchers on investigative pathology and contributes to diagnostic services. Education: DVM (University of Belgrade), DVSc (University of Guelph), ACVP Diplomate Key Research Themes: Honey bee health, infectious disease pathogenesis, antimicrobial resistance, and diagnostic pathology Collaborations: Prairie Diagnostic Services, multiple veterinary and agricultural researchers Dr. Simko’s publications span veterinary pathology, honey bee health, and equine medicine. His recent articles highlight advancements in diagnostic techniques for septic arthritis in horses and interventions to mitigate honey bee colony threats. He has no listed awards but maintains active roles in teaching and applied research.

• Bioethics
• Clinical Ethics
• Health Care Ethics
• +۳ مورد دیگر

Catherine Bert is a Researcher affiliated with the University of Namur (UNamur), based in the Center for Vulnerabilities and Societies Transitions within the Philosophical Space of Namur. She holds a Doctorate in Philosophy (UNamur) and multiple diplomas in Sociology, International Relations, and Comparative Politics from Université catholique de Louvain (UCL). Her academic roles include being a Professor of Philosophy, Ethics, Anthropology, and Sociology at the IES Parnasse-Deux-Alice in Brussels, a member of the ethics committee at CHR de la Haute Senne, and an editorial board member of the journal Les politiques sociales . Research Interests: Dr. Bert specializes in clinical ethics, bioethics, and pandemic-related healthcare ethics. Her work intersects with sociological and anthropological perspectives, focusing on solidarity practices, care ethics, and gender-based violence in medical contexts. She actively contributes to the United Nations Sustainable Development Goals, particularly in eradicating poverty and promoting health equity. Projects & Activities: She has led or collaborated on projects like the 'Universality of Values in Bioethics' and 'Virtue Ethics in Care Practices Analysis'. Her research spans ethical dilemmas in healthcare, including reproductive rights and pandemic response. She frequently participates in workshops, conferences, and colloquia on ethics and healthcare, such as the 'Certificat interUniversitaire en Éthique des Soins de Santé (CUESS)'. Publications: Her recent work addresses solidarity initiatives, crisis care ethics, and gender violence in reproductive healthcare. She also explores molecular mechanisms in skin diseases, including fungal infections and epidermal barrier dysfunction. Affiliations & Roles: Beyond academia, she advises on ethical committees and editorial boards, emphasizing translational ethics into policy and practice.

Alanna (Leni) Greenمشاهده پروفایل

پژوهشگر ارشد

• Bone-Immune-Cancer Interactions
• Cancer Dormancy
• Retinoic Acid Receptor Signaling
• +۳ مورد دیگر

Dr. Alanna (Leni) Green is a Senior Research Fellow at the School of Medicine and Population Health, University of Sheffield. She leads the Cancer and Bone (CAB) Lab, focusing on eradicating chemotherapy-resistant dormant cancer cells in bone. Her academic journey includes a BBiomedSci at Monash University, a PhD at the University of Melbourne, and postdoctoral roles in the Sheffield Myeloma Research Team and Helleday’s lab. Education: BBiomedSci (Hons), Monash University PhD, University of Melbourne Her research explores bone-immune-cancer interactions, particularly how bone microenvironment cells protect tumors from therapy. Key areas include retinoic acid receptor signaling, vitamin A regulation of hematopoiesis, and novel drug development for myeloma and bone-metastatic cancers. Recent publications highlight her work in cancer metabolism (MTHFD2 inhibition), bone repair mechanisms, and microenvironmental regulation of lymphopoiesis. She has received over 20 awards, including Young Investigator Prizes from ECTS and ASBMR. Scientific Awards: Wellcome Trust Career Development Award (2024) Yorkshire Cancer Research Pioneer Advanced Fellowship (2024) Blood Cancer UK Project Grant (2023) Faculty MDH Early Career Researcher Prize (2020) Dr. Green supervises the Cancer and Bone Lab, which includes postdoctoral researchers and PhD students. She lectures on translational oncology and molecular medicine courses and actively contributes to professional societies like the Bone Research Society and ECTS.

Grant Michelsonمشاهده پروفایل

استاد

• Business Ethics
• Corporate Social Responsibility (CSR)
• Organizational Behavior
• +۳ مورد دیگر

Grant Michelson is a Professor of Management in the Department of Management at Macquarie Business School, Macquarie University. He has held leadership roles including Chair of the Department of Management (2016–2019), interim Associate Dean for Learning & Teaching, and Academic Senate member (2021–2026). His research focuses on business ethics, corporate social responsibility (CSR), organizational behavior, and workplace dynamics, with notable contributions to modern slavery eradication, auditor transparency, and pandemic-era ethics. Michelson has extensive international experience, including roles at Audencia Business School (France) and visiting positions at institutions like the University of Zagreb and University of Sydney. Education: Qualifications from the Universities of Canterbury, Otago, and Sydney. Leadership: Served on review panels for UNSW, Griffith University, and others. Research: Over 70 publications, including studies on workplace gossip, industrial relations, and CSR strategies. Projects: Led initiatives on accounting career pathways and early-career skills. Collaborations: Global networks with institutions in China, France, and Croatia. Research Interests: Combines ethical theory with practical challenges, emphasizing CSR in crises, modern slavery, and the impact of technology on work. Recent work explores post-pandemic workplace ethics and NGO roles in human rights advocacy. Grants & Projects: Includes studies on auditor transparency (2024), sustainable accounting careers (2020–2021), and early-career accountant skill gaps (2020). Lab/Teams: Active in Macquarie Business School research groups and international advisory boards.

Mark Smeltzerمشاهده پروفایل

استاد

• Bacterial Pathogenesis
• Antimicrobial Resistance
• Infectious Disease
• +۴ مورد دیگر

Mark Smeltzer is a Professor in the Department of Microbiology and Immunology and Department of Orthopaedics at the University of Arkansas for Medical Sciences (UAMS). He specializes in the molecular pathogenesis of Staphylococcus aureus infections, particularly focusing on its role in orthopaedic infections, biofilm formation, and antibiotic resistance mechanisms. His work integrates molecular biology, proteomics, and nanotechnology to develop novel therapeutic strategies. Dr. Smeltzer earned his Ph.D. from Kansas State University and completed postdoctoral training under Dr. John J. Iandolo. His research is supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID), the Congressionally-Directed Medical Research Program, and the Texas Hip and Knee Foundation. Key collaborations include projects with Dr. Jingyi Chen (nanotherapeutics) and Dr. Alexandru Biris (bone regeneration scaffolds). Research Interests: Mechanisms of S. aureus biofilm formation and antibiotic resistance Role of the sarA regulatory gene in virulence and infection Development of nanoparticle-based therapies for biofilm-associated infections Orthopaedic device-related infections and bone regeneration Key Findings: Identified sarA mutations limiting biofilm formation and enhancing antibiotic susceptibility Developed gold nanocage-based systems for targeted antibiotic delivery and photothermal therapy Discovered protease-dependent virulence factors critical for infection progression Funding Highlights: NIAID grants for sarA regulatory pathway studies Congressionally-Directed Medical Research Program grants for small molecule inhibitors Collaborative grants for nanotherapeutic and bone regeneration projects Dr. Smeltzer’s lab actively explores translational approaches to combat antibiotic-resistant infections, with a focus on clinical applications in orthopaedics and infectious diseases.

Amr Fawzy Moussaمشاهده پروفایل

دانشیار

• Dental Biomaterials
• Nano-dentistry
• High-Intensity Focused Ultrasound (HIFU) Applications
• +۵ مورد دیگر

Amr Fawzy Moussa is an Associate Professor at the Dental School of the University of Western Australia (UWA), leading the Biomaterials and Nano-dentistry research group. He holds roles as Head of the Division of Oral Restorative and Rehabilitative Sciences and Unit Coordinator for courses such as DENT 4232, DENT 4236, and DENT 3007. Previously, he worked at Ain Shams University and the National University of Singapore, focusing on Dental Biomaterials and Restorative Dentistry. His research interests span Dental Biomaterials, High-Intensity Focused Ultrasound (HIFU) applications in dentistry, nano-dentistry, and regenerative therapies. Current projects include HIFU-enhanced dental adhesion, 3D-printed self-healing materials, and anti-biofilm strategies. His work is funded by NHMRC, Australian Dental Research Foundation, Colgate, and industry partnerships. Prof. Moussa supervises PhD and HDR students and collaborates internationally with institutions in Asia-Pacific, Europe, and the USA. He serves on editorial boards for journals like Frontiers in Dental Medicine and is a NHMRC grant assessment panel member. His recent publications (2025) emphasize HIFU's role in dentin bonding, enamel remineralization, and biofilm eradication, reflecting his lab's focus on innovative materials and technologies for clinical dentistry.

Emanuel Petricoinمشاهده پروفایل

استاد

• Proteomics
• Molecular Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Emanuel Petricoin is a Professor and Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University's School of Systems Biology, a position held since 2005 with prior leadership at the FDA-NCI Clinical Proteomics Program (1993-2005). His academic affiliation spans proteomics, molecular medicine, and precision oncology within GMU's research ecosystem. His educational background includes: Ph.D. in Microbiology from the University of Maryland, College Park (1990) Dr. Petricoin pioneers clinical proteomics for personalized therapy and biomarker discovery, with seminal work in cancer signaling pathways, tumor microenvironment analysis, and diagnostic assay development. His research integrates proteogenomics, phosphoproteomics, and functional protein analysis to address therapeutic resistance in breast and pancreatic cancers. As a translational scientist, he bridges laboratory innovation with clinical implementation through FDA-regulated platforms. Analysis of his 2024-2025 publications reveals dominant themes in proteogenomic tumor characterization, KRAS/HER2 pathway dynamics, and biomarker-guided immunotherapy. Key trends include spatial proteomics of tumor heterogeneity, extracellular vesicle-mediated signaling, and quantitative assessment of drug targets for precision oncology decision-making. The work consistently emphasizes clinical applicability through CLIA-certified assays and molecular tumor boards. His scientific recognition includes: University Professorship at George Mason University NIH Director’s Award FDA Distinguished Scientist Award 2015 Innovator of the Year Award GAP50 Top Virginia Entrepreneurs Nifty 50 Award American Society of Cytopathology Basic Research Award Roche Diagnostics/CLAS Distinguished Scientist Award Harvard University Leading Edge Award Dr. Petricoin drives research commercialization as co-founder of four biotech firms (Theranostics Health, Ceres Nanosciences, C-4 Diagnostics, Perthera) and co-inventor of 40+ patents. His editorial leadership spans Proteomics, Cancer Epidemiology Biomarkers and Prevention, and other high-impact journals. He actively shapes national initiatives as a HUPO founding member and Virginia Health Research Biosciences Corporation board representative. The CAPMM under his co-direction serves as a national hub for clinical proteomics, specializing in reverse-phase protein array (RPPA) technology, laser capture microdissection, and biomarker validation for direct patient care applications. The center integrates multi-omic data to advance personalized cancer therapy through industry partnerships and clinical trial support.

Suren Tatulianمشاهده پروفایل

استاد

• Molecular Biophysics
• Biotechnology
• Protein Structure and Function
• +۶ مورد دیگر

Dr. Suren Tatulian is a Professor in the Department of Physics at the University of Central Florida (UCF), with a joint affiliation at the Biomolecular Sciences Center. He holds a BS in Physics from Yerevan State University, Armenia, and a PhD in Biology from the Institute of Cell Biology, St. Petersburg, Russia. Research Focus: Molecular biophysics, protein-membrane interactions, amyloidogenesis, interfacial enzymology, and neurodegenerative disease mechanisms. Key Techniques: Protein engineering, spectroscopy (FTIR, fluorescence), computational modeling, and structural analysis of toxins and amyloid peptides. His recent work explores amyloid β peptide behavior in lipid membranes, cholera toxin disassembly mechanisms, and peptide-based inhibitors of neurotoxic aggregation. Dr. Tatulian has mentored students in biophysical research and leads studies on membrane pore formation and protein folding dynamics. Lab Affiliation: Biomolecular Sciences Center at UCF, where he investigates biophysical aspects of neurodegenerative diseases and toxin translocation.

• Exercise Oncology
• Cancer Rehabilitation
• Prostate Cancer Treatment
• +۳ مورد دیگر

Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.

• Vaccine Impact Modelling
• Infectious Disease Epidemiology
• Health Economics
• +۳ مورد دیگر

Dr. Kaja Abbas is an Associate Professor in Infectious Disease Epidemiology and Dynamics at the London School of Hygiene & Tropical Medicine (LSHTM), with a joint position at Nagasaki University. He leads research at the intersection of vaccine impact modeling, health economics, and epidemiology, focusing on evidence-based vaccination strategies for global health equity. His work spans low-, middle-, and high-income countries, supported by affiliations with LSHTM’s Centre for Mathematical Modelling of Infectious Diseases, Vaccine Centre, and Centre for Epidemic Preparedness and Response. His research examines the health, economic, and equity impacts of vaccination programs through mathematical modeling. Key interests include: Estimating vaccine value for diseases like typhoid, HPV, and COVID-19 Analyzing immunization disruptions during pandemics Assessing cost-effectiveness of novel vaccine delivery strategies Identifying barriers to vaccine access in marginalized populations Publications demonstrate consistent focus on translating modeling insights into policy, with recurring themes of outbreak preparedness, antimicrobial resistance, and equity-focused vaccine deployment. Recent work emphasizes economic burden analyses and stakeholder-driven approaches for vaccine introduction in endemic regions. Grant funding includes 16 active and completed projects from major health organizations: Bill & Melinda Gates Foundation (nutrition-vaccination integration in Chad/Niger) WHO (vaccine value against antimicrobial resistance) GAVI (measles-rubella impact assessment) International Vaccine Institute (typhoid/chikungunya vaccine feasibility) He currently serves on the UK Joint Committee on Vaccination and Immunisation (JCVI), influencing national immunization policy.

Sonam Parakhمشاهده پروفایل

پژوهشگر ارشد

• Amyotrophic Lateral Sclerosis (ALS)
• Frontotemporal Dementia with Motor Neuron Disease
• Molecular Origins of Neurodegenerative Diseases
• +۴ مورد دیگر

Sonam Parakh is a Research Fellow at the Motor Neuron Disease Research Centre within Macquarie Medical School , Macquarie University , where she has worked since 2017. Her research focuses on elucidating the molecular origins of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) , with a particular emphasis on endoplasmic reticulum stress, protein misfolding, and therapeutic target development. Education: PhD in Neuroscience (2016, Macquarie University) MSc in Biotechnology and Bioinformatics (2012, La Trobe University) BSc in Biotechnology (2009, Bangalore University) Her research explores TDP-43 pathology , C9orf72 dipeptide repeats , and ER-Golgi trafficking in ALS/FTD. Recent projects include: MNDRA Innovator : Targeting TDP-43 with nucleoredoxin (NRX) gene therapy (2023-2024) MND 24 : Investigating GABAA agonists against TDP-43 pathology (2025-2026) Her publications highlight roles for protein disulfide isomerases , redox activity , and cyclin F mutations in neurodegenerative disease mechanisms. Current collaborations involve researchers like J. Atkin , V. Gupta , and C. Blair , with affiliations to Macquarie University’s centralized biobank project (2015-2019) and the Centre for Motor Neuron Disease Research (2017-2019).

• Parasitic Nematode Drug Development
• Antimicrobial Therapeutics
• Medical Entomology
• +۳ مورد دیگر

Dr. Mostafa Elfawal is an Assistant Professor at UMass Chan Medical School in the Program in Molecular Medicine, affiliated with the T.H. Chan School of Medicine. His research focuses on developing novel therapeutics against parasitic infections, particularly targeting soil-transmitted helminths and malaria. He completed his PhD in Medical Entomology/Microbiology at the University of Massachusetts Amherst, following a BA and MS in Animal Science from Ain Shams University in Egypt. His work emphasizes high-throughput drug screening and repurposing existing compounds for anthelmintic use, with recent breakthroughs in PIM kinase inhibitors and broad-spectrum antiparasitic agents. He has extensively studied Artemisia annua's antimalarial properties and its role in overcoming drug resistance. Collaborations with institutions like the NIH and international networks highlight his global impact in parasitology and tropical medicine. Key contributions include identifying metabolic enzyme inhibitors as anthelmintics, elucidating hookworm's cognitive and microbiome effects, and advancing yeast particle encapsulation for controlled drug release. His research bridges basic science with clinical application, addressing critical gaps in treating neglected tropical diseases.